

## QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE

Name of the Company : ASTRAZENECA PHARMA INDIA LIMITED  
 Scrip Code : BgSE: ASTRAZEN / BSE: 506820 / NSE: ASTRAZEN  
 Quarter ending on : March 31, 2012

Particulars	Clause of Listing agreement	Compliance Status Yes/No	Remarks
<b>I. Board of Directors</b>	49 (I)		
(A) Composition of Board	49 (IA)	Yes	
(B) Non-executive Directors' compensation & disclosures	49 (IB)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012
(C) Other provisions as to Board and Committees	49 (IC)	Yes	
(D) Code of Conduct	49 (ID)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012
<b>II. Audit Committee</b>	49 (II)		
(A) Qualified & Independent Audit Committee	49 (IIA)	Yes	
(B) Meeting of Audit Committee	49 (IIB)	Yes	
(C) Powers of Audit Committee	49 (IIC)	Yes	
(D) Role of Audit Committee	49 II(D)	Yes	
(E) Review of Information by Audit Committee	49 (IIE)	Yes	
<b>III. Subsidiary Companies</b>	49 (III)	NA	There is no subsidiary
<b>IV. Disclosures</b>	49 (IV)		
(A) Basis of related party transactions	49 (IV A)	Yes	Will be placed before the Audit Committee meeting to be held on May 11, 2012.
(B) Disclosure of Accounting Treatment	49 (IV B)	Yes	
(C) Board Disclosures	49 (IV C)	Yes	
(D) Proceeds from public issues, rights issues, preferential issues etc.	49 (IV D)	NA	No proceeds from public issues, rights issue, preferential issues etc.
(E) Remuneration of Directors	49 (IV E)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012
(F) Management	49 (IV F)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012
(G) Shareholders	49 (IV G)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012
<b>V. CEO/CFO Certification</b>	49 (V)	Yes	Will be placed before the Board at the Meeting to be held on May 11, 2012.
<b>VI. Report on Corporate Governance</b>	49 (VI)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012
<b>VII. Compliance</b>	49 (VII)	Yes	Will be disclosed in the Annual Report for the year ended March 31, 2012

For AstraZeneca Pharma India Limited

Himanshu Agarwal  
 Chief Financial Officer

CORPORATE & REGD OFFICE  
 AstraZeneca Pharma India Ltd.  
 P.B.No.2483, Off Bellary Road  
 Hebbal  
 Bangalore - 560 024  
 INDIA

TEL : +91 80 67748000  
 FAX : +91 80 23622015  
 www.astrazenecaindia.com

FACTORY  
 12' Mile on Bellary Road  
 Venkataka, Kattigenahalli Village  
 Yelahanka, Bangalore - 560 063  
 INDIA

TEL : +91 80 6774 9000  
 +91 80 2846 0071  
 +91 80 2849 0430  
 +91 80 2846 0158  
 FAX : +91 80 2846 2202